For small‑vessel (<2 mm) or bifurcation intracranial aneurysms, what is the preferred endovascular treatment and antiplatelet regimen, and when is flow‑diverter use appropriate?

Flow Diversion for Small Vessel and Bifurcation Aneurysms

For small-vessel (≤2 mm) and bifurcation intracranial aneurysms, flow diverter stents are appropriate and effective, with hydrophilic polymer-coated devices under prasugrel single antiplatelet therapy demonstrating superior safety profiles compared to traditional dual antiplatelet regimens.

Small-Vessel Aneurysms (≤2 mm)

Flow Diverter Selection and Outcomes

Flow diverters are now a viable first-line option for aneurysms arising from vessels ≤2 mm in diameter. The most recent evidence demonstrates that hydrophilic polymer-coated (HPC) p48 MW flow diverters achieve 71.9% complete occlusion at 3-6 months and 86.1% at 12 months, with only 3.2% complication rates 1. This represents a significant advancement over historical concerns about flow diverter use in distal, small-caliber vessels.

The key technical consideration is that these devices can be deployed with high technical success (100% in recent series) even in challenging distal anatomy 1. No cases of aneurysm rupture or hemorrhagic complications were recorded in the largest recent cohort, addressing previous safety concerns.

Antiplatelet Regimen

Prasugrel single antiplatelet therapy (SAPT) is the preferred regimen for flow diverter treatment in small vessels, based on the most recent high-quality evidence 1. This represents a paradigm shift from traditional dual antiplatelet therapy (DAPT).

The evidence hierarchy for antiplatelet selection:

• Prasugrel monotherapy: 2.4% thromboembolic complication rate (95% CI 0-9.3%) 2
• Ticagrelor monotherapy: 4.2% rate (95% CI 0.1-21.1%) 2
• Aspirin monotherapy: 20.2% rate (95% CI 5.9-38.6%) - significantly inferior 2

The hemorrhagic complication rate with SAPT is exceptionally low at 0.1% (95% CI 0-1.8%), with overall mortality of 1.3% 2. Prasugrel specifically demonstrates superior efficacy compared to aspirin while maintaining an acceptable safety profile 2, 3.

Clinical Algorithm for Small-Vessel Aneurysms

1. Confirm vessel diameter ≤2 mm on high-resolution angiography
2. Select hydrophilic polymer-coated flow diverter (e.g., p48 MW HPC device)
3. Initiate prasugrel SAPT pre-procedurally
4. Deploy flow diverter with meticulous microwire navigation
5. Follow-up imaging at 3-6 months, then 12 months

Bifurcation Aneurysms

Flow Diverter Appropriateness

Bifurcation aneurysms present unique anatomical challenges—they are typically wide-necked and involve side-branch arteries. Flow diversion is appropriate for bifurcation aneurysms in highly selective cases, though this remains an off-label application 4. The 2025 evidence demonstrates that flow diversion achieves satisfactory occlusion with favorable angiographic outcomes in carefully selected bifurcation cases 4.

Critical Selection Criteria

Bifurcation location is the dominant independent predictor of recanalization after stent-assisted coiling (OR 9.02; p = 0.001) 5, making flow diversion particularly relevant for these challenging lesions. However, wider aneurysm neck diameter independently predicts incomplete flow diverter occlusion (adjusted OR 1.23/mm; p = 0.044) 5.

Antiplatelet Management for Bifurcation Aneurysms

For bifurcation aneurysms, the antiplatelet approach differs slightly from small-vessel aneurysms:

• DAPT (aspirin + clopidogrel) remains the standard for most bifurcation cases 6, 3
• Average efficacy of clopidogrel-aspirin DAPT: 88% (95% CI, SD ±5%) with acceptable hemorrhagic and thromboembolic complication rates 6
• Consider prasugrel or ticagrelor as alternatives to clopidogrel in patients with documented clopidogrel resistance or genetic polymorphisms affecting metabolism 3

Clinical Algorithm for Bifurcation Aneurysms

1. Assess aneurysm neck width and side-branch involvement on 3D rotational angiography
2. Determine if endovascular treatment is feasible versus microsurgical clipping
3. If flow diversion selected:
   • Initiate DAPT (aspirin + clopidogrel) at least 5-7 days pre-procedure
   • Consider platelet function testing to guide P2Y12 inhibitor selection 3
   • Deploy flow diverter covering aneurysm neck while preserving critical side branches
4. Maintain DAPT for minimum 3-6 months, then transition to aspirin monotherapy
5. Serial angiographic follow-up at 6 months, 12 months, then annually

Guideline Framework and Caveats

The 2015 AHA/ASA guidelines emphasize that treatment decisions must consider aneurysm size, location, morphology, patient age, and center volume 7. Treatment should be performed at high-volume centers (Class I, Level B) 7. While these guidelines predate the most recent flow diverter evidence, they establish that endovascular therapy may be reasonable over surgical clipping for select aneurysms, particularly when surgical morbidity is high 7.

Common Pitfalls to Avoid

1. Do not use aspirin monotherapy for flow diverter cases—it carries unacceptably high thromboembolic rates (20.2%) 2
2. Do not assume all bifurcation aneurysms are suitable for flow diversion—this requires expert case selection 4
3. Do not neglect platelet function testing in patients on clopidogrel, as genetic variability significantly affects response 3
4. Do not treat at low-volume centers—outcomes are demonstrably inferior 7

Special Considerations for Ruptured Aneurysms

For ruptured small-vessel or bifurcation aneurysms, early flow diverter implantation (within 7 days) can achieve 84.6% favorable functional outcomes (mRS 0-2) with 100% technical success 8. However, this requires:

• Standardized DAPT protocols despite SAH hemorrhagic risk
• Rigorous hemodynamic management
• Ideal case selection (small saccular, blister-like, or fusiform morphology) 8

The mortality rate of 15.4% in ruptured cases is attributable to the initial SAH, not the flow diverter procedure itself 8.

Emerging Evidence and Future Directions

The 2026 ESO/EANS/ESMINT guidelines on aneurysmal SAH recommend treating ruptured aneurysms within 24 hours when the most dedicated expert team is available 9. While these guidelines do not specifically address flow diverters for small vessels or bifurcations, they emphasize treatment at centers managing ≥70 aSAH patients annually (or ≥35 in remote areas) 9.

Drug-eluting flow diverters and P2Y12 inhibitor reversal agents represent the next frontier in refining antiplatelet strategies 3, though these remain investigational.